» Articles » PMID: 18059336

Ets-2 and P160 Proteins Collaborate to Regulate C-Myc in Endocrine Resistant Breast Cancer

Overview
Journal Oncogene
Date 2007 Dec 7
PMID 18059336
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Associations between p160 coactivator proteins and endocrine resistance have been described. Though thought to primarily interact with steroid receptors, the p160 proteins can also interact with non-nuclear receptor transcription factors including the MAP kinase effector proteins Ets. Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc. Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3. In support of these molecular observations, strong associations were observed between the transcription factor, Ets-2 and its coactivator SRC-1 (P<0.01) and the target gene myc (P<0.0001) in a cohort of breast cancer patients with locally advanced disease. Expression of Ets-2, SRC-1 and c-Myc individually all associated with reduced disease-free survival (P<0.001, P<0.001 and P=0.002 respectively). There was no association between SRC-3 and disease-free survival (P=0.707). SRC-1 can utilize MAP kinase effector transcription factor Ets-2 to regulate the production of the oncogene myc. These signalling mechanisms may be important in the development of steroid resistant/independent breast cancer.

Citing Articles

Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer.

Chen J, Wu C, Yu K, Liu J, Yang J, Li W J Cancer Res Clin Oncol. 2025; 151(2):71.

PMID: 39921753 PMC: 11807082. DOI: 10.1007/s00432-025-06124-x.


Function of Steroid Receptor Coactivators in T Cells and Cancers: Implications for Cancer Immunotherapy.

Zhang W, Cao X, Wu H, Zhong X, Shi Y, Sun Z Crit Rev Immunol. 2024; 44(6):111-126.

PMID: 38848298 PMC: 11902286. DOI: 10.1615/CritRevImmunol.2024051613.


The multifaceted therapeutic value of targeting steroid receptor coactivator-1 in tumorigenesis.

Chen Q, Guo P, Hong Y, Mo P, Yu C Cell Biosci. 2024; 14(1):41.

PMID: 38553750 PMC: 10979636. DOI: 10.1186/s13578-024-01222-8.


Steroid receptor coactivator 1 promotes human hepatocellular carcinoma invasiveness through enhancing MMP-9.

Tong Z, Zhang Y, Guo P, Wang W, Chen Q, Jin J J Cell Mol Med. 2024; 28(7):e18171.

PMID: 38506084 PMC: 10951881. DOI: 10.1111/jcmm.18171.


Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Jafari H, Hussain S, Campbell M Cancers (Basel). 2022; 14(10).

PMID: 35626007 PMC: 9139824. DOI: 10.3390/cancers14102402.